Ovarian Antibody Screen with Reflex to Titer, IFA

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: Ovarian Antibody Screen With Reflex To Titer IFA

Anti-Ovary Ab Titer

Anti-Ovary Antibody

*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through Quest Diagnostics. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 Quest Diagnostics laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The Ovarian Antibody Screen with Reflex to Titer, IFA test contains 1 test with 2 biomarkers.

Ovarian Antibody Screen with Reflex to Titer, IFA

  • If Ovarian Antibody Screen is positive, then Ovarian Antibody Titer will be performed at an additional charge (CPT code(s): 86256).


Immunofluorescence Assay (IFA)

Assay Category

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Reference Range(s)

Anti-Ovary Antibody Negative
   Anti-Ovary Ab Titer <1:5


The Ovarian Antibody Screen with Reflex to Titer, IFA (Indirect Immunofluorescence Assay) is a laboratory test used to detect and measure the presence of antibodies against ovarian tissue in a person's blood. This test is primarily used to aid in the diagnosis of autoimmune disorders that can affect the ovaries.

Here's how the test works:

  1. Sample collection: A blood sample is collected from the patient, usually through a vein in the arm.

  2. Ovarian Antibody Screen: The blood sample is sent to a laboratory, where it undergoes an initial screening test. In this step, the patient's serum is mixed with ovarian tissue antigens. If antibodies against the ovarian tissue are present in the serum, they will bind to the antigens.

  3. Immunofluorescence Assay (IFA): If the initial screening test is positive, the sample is subjected to an IFA. In this step, the mixture of patient serum and ovarian tissue antigens is exposed to a fluorescent dye-labeled antibody that specifically binds to human antibodies. If ovarian antibodies are present in the patient's sample, they will bind to the ovarian tissue antigens. The fluorescent dye-labeled antibody will then bind to the patient's antibodies, forming a visible complex.

  4. Microscopic examination: The sample is examined under a fluorescence microscope. If the patient's serum contains antibodies against ovarian tissue, the complex formed in the previous step will emit fluorescence when illuminated with the appropriate light wavelength. This fluorescence indicates a positive result, suggesting the presence of ovarian-specific autoantibodies.

  5. Reflex to Titer: If the initial screening test is negative, the reflex to titer may not be performed. However, if the initial screening test is positive, the laboratory may perform a titer determination. The titer represents the relative concentration of antibodies in the patient's blood. It involves diluting the patient's serum and retesting it to determine the highest dilution at which the antibodies can still be detected. The titer can provide additional information about the antibody levels and their clinical significance.

The Ovarian Antibody Screen with Reflex to Titer, IFA is a useful tool for identifying autoimmune conditions affecting the ovaries, such as autoimmune oophoritis or ovarian autoimmunity. It is important to note that a positive test result does not necessarily confirm a specific diagnosis. Further clinical evaluation and additional tests may be required to establish a definitive diagnosis and guide appropriate treatment. It is always best to consult with a healthcare professional or a specialist, such as a rheumatologist or an endocrinologist, for proper interpretation and management of test results.

Customer Reviews